Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients.
Alexandre E MalekJavier A AdachiVictor E MulanovichJoseph SassineIssam I RaadKelly McConnGarret T SeilerUdit DhalFareed KhawajaRoy F ChemalyPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2021)
Severe acute respiratory syndrome coronavirus 2 can lead to life-threatening coronavirus disease 2019 (COVID-19) infections in patients with hematologic malignancies, particularly among hematopoietic cell transplant (HCT) recipients. We describe two patients with COVID-19 during the pre-engraftment period after HCT and review previous reports of COVID-19 in HCT recipients. Because of significant mortality from COVID-19, primarily after allogeneic HCT, early, preemptive, and optimal directed therapy may improve outcomes and reduce the mortality rate but still needs to be established in clinical trials.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- bone marrow
- clinical trial
- cell cycle arrest
- single cell
- cell therapy
- cardiovascular events
- risk factors
- randomized controlled trial
- type diabetes
- adipose tissue
- mesenchymal stem cells
- low dose
- cell death
- cardiovascular disease
- study protocol
- coronary artery disease
- kidney transplantation
- adverse drug
- smoking cessation
- signaling pathway